Zinforo® Microbiology in cSSTI

Zinforo® : Optimising outcomes for cSSTI patients*1-5,7

*There is no experience with Zinforo® in the treatment of cSSTI in the following patient groups:
The immunocompromised; patients with severe sepsis/septic shock, necrotising fasciitis, perirectal abscess and patients with third-degree and extensive burns.
There is limited experience in treating patients with diabetic foot infections. Caution is advised when treating such patients.1
†Potency has been demonstrated in clinical studies of cSSTI against pathogens that were susceptible to antibiotics in vitro. In vitro activity does not always correlate with clinical efficacy.

cSSTI: complicated skin and soft tissue infections; MIC: minimum inhibitory concentration

References:
1. ZINFORO® (ceftaroline fosamil). Summary of Product Characteristics. Pfizer. 2019.
2. Corey G, Wilcox M, Talbot G, et al. Clin Infect Dis 2010; 51:641–50.
3. Corey G, Wilcox M, Talbot G, et al. J Antimicrob Chemother 2010;65(Suppl. 4):iv41–iv51.
4. Wilcox M, Corey G, Talbot G, et al. J Antimicrob Chemother 2010;65(Suppl. 4):iv53–iv65.
5. Garrison MW, Kawamura NM, Wen MM. Expert Rev Anti Infect Ther 2012; 10:1087–103.
6. Drusano GL. J Antimicrob Chemother 2011; 66(Suppl. 3):iii61–iii67.
7. Casapao AM, Davis SL, Barr VO, et al. Antimicrob Agents Chemother 2014; 58:2541–6.

MIC breakpoints established by the CLSI for ZINFORO:

In vitro susceptibility testing breakpoints1,2

In vitro activity does not always correlate with clinical efficacy.

Efficacy has been demonstrated in CAP clinical studies against the following pathogens that were susceptible to ceftaroline in vitro. Streptococcus pneumoniae, Staphylococcus aureus (methicillin-susceptible strains only), Escherichia coli, Haemophilus influenzae, Haemophilus parainfluenzae, and Klebsiella pneumoniae.

Efficacy has been demonstrated in clinical studies of cSSTI against pathogens that were susceptible to ZINFORO® in vitro.1

†The breakpoint for susceptible is based on a dosage regimen of ceftaroline 600 mg administered every 12 h.2
‡ The available clinical data cannot substantiate efficacy against penicillin non-susceptible strains of Streptococcus pneumoniae. In vitro data indicate that the following atypical species are not susceptible to ZINFORO®: Chlamydophila spp., Legionella spp., Mycoplasma spp, Proteus spp. and Pseudomonas aeruginosa.1

MIC breakpoints established by the EUCAST for ZINFORO:

In vitro susceptibility testing breakpoints 1,3

In vitro activity does not always correlate with clinical efficacy.

*Efficacy has been demonstrated in CAP clinical studies against the following pathogens that were susceptible to ceftaroline in vitro. Streptococcus pneumoniae, Staphylococcus aureus (methicillin-susceptible strains only), Escherichia coli, Haemophilus influenzae, Haemophilus parainfluenzae, and Klebsiella pneumoniae. Efficacy has been demonstrated in clinical studies of cSSTI against pathogens that were susceptible to ZINFORO®in vitro.1

Refers to dosing of adults or adolescents (from 12 years and 33 kg) with ceftaroline every 12 hours using 1-hour infusions.1
Refers to dosing of adults or adolescents (from 12 years and 33 kg) with ceftaroline every 8 hours using 2-hour infusions to treat cSSTI. Staphylococcus aureus with ceftaroline MICs ≥4 mg/mL are rare. PK/PD analyses suggest that dosing of adults or adolescents (from 12 years and 33 kg) with ceftaroline every 8 hours using 2-hour infusions may treat cSSTI due to Staphylococcus aureus for which ceftaroline MIC is 4 mg/mL.1

§The available clinical data cannot substantiate efficacy against penicillin non-susceptible strains of Streptococcus pneumoniae. In vitro data indicate that the following atypical species are not susceptible to ZINFORO®: Chlamydophila spp., Legionella spp., Mycoplasma spp, Proteus spp. and Pseudomonas aeruginosa.1
IIInferred by susceptibility to benzylpenicillin.3

ZINFORO® is a fifth-generation cephalosporin with coverage against key pathogens in cSSTI and CAP, including S. aureus and S. pneumoniae.1,4

Clinical efficacy has been demonstrated against the following pathogens in cSSTI1:

cSSTI: complicated skin and soft tissue infections; CAP: community acquired pneumonia; MIC: minimum inhibitory concentration; PK/PD: Pharmacokinetic/Pharmacodynamic

References:
1. ZINFORO® (ceftaroline fosamil). Local Product Document of Ceftaroline; LPDZIN072021.
2. CLSI 2019 Performance Standards for Antimicrobial Susceptibility Testing, 29th Edition. Available at: http://em100.edaptivedocs.net/GetDoc.aspx?doc=CLSI%20M100%20ED29:2019&scope=user (last accessed September 2021).
3. European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters. Available at: http://mic.eucast.org/Eucast2/. Last accessed 5 September, 2016.
4. Laudano JB. J Antimicrob Chemother 2011;66(Suppl 3):iii11–8;

Consistently low MIC values – a potent addition to the treatment options for cSSTI* 1,2

*Potency has been demonstrated in clinical studies of cSSTI against pathogens that were susceptible to antibiotics in vitro. In vitro activity does not always correlate with clinical efficacy.

cSSTI: complicated skin and soft tissue infections; MIC: minimum inhibitory concentration

References:
1. Corey G, Wilcox M, Talbot G, et al. Clin Infect Dis 2010; 51:641–50.
2. Garrison MW, Kawamura NM, Wen MM. Expert Rev Anti Infect Ther 2012; 10:1087–103.

PP-ZFO-IND-0279.  09 December 2021
Please click on Prescribing Information link to view safety and adverse events information of Zinforo.
For the use only of registered medical practitioner, or a hospital or a laboratory.